Tonix Pharmaceuticals Holding Investor Presentation — September 2021 - Tonix Pharmaceuticals Holding Corp.

Document content

September 2021Investor Presentation

Certain statements inthispresentation regarding strategic plans, expectations andobjectives forfuture

operations orresults are“forward -looking statements” asdefined bythePrivate Securities Litigation Reform

Actof1995.These statements may beidentified bytheuseofforward -looking words such as“anticipate,”

“believe,” “forecast,” “estimate” and“intend,” among others .These forward -looking statements arebased on

Tonix’s current expectations andactual results could differ materially .There areanumber offactors that

could cause actual events todiffer materially from those indicated bysuch forward -looking statements. These

factors include, butarenotlimited to,risks related tofailure toobtain U.S.Food andDrug Administration

clearances orapprovals andnoncompliance withitsregulations ;ourneed foradditional financing ;delays and

uncertainties caused bytheglobal COVID -19pandemic; substantial competition ;uncertainties ofpatent

protection andlitigation ;uncertainties ofgovernment orthird party payor reimbursement ;limited research

anddevelopment efforts anddependence upon third parties .Aswithanypharmaceutical under development,

there aresignificant risks inthedevelopment, regulatory approval andcommercialization ofnewproducts .

Theforward -looking statements inthispresentation aremade asofthedate ofthispresentation, even if

subsequently made available byTonix onitswebsite orotherwise .Tonix does notundertake anobligation to

update orrevise anyforward -looking statement, except asrequired bylaw.Investors should read therisk

factors setforth intheAnnual Report onForm 10-Kfortheyearended December 31,2020,asfiledwiththe

Securities andExchange Commission (the“SEC”) onMarch 15,2021, andperiodic reports andcurrent reports

filed with theSEConorafter thedate thereof .AllofTonix's forward -looking statements areexpressly

Clinical -stage biopharmaceutical company that invents, licenses, acquires and develops

innovative medicines to help patients manage central nervous system (CNS) and immunology

“Advancing science to improve patient care and public health”

Team of passionate professionals

Advancing innovative programs into the clinic: Phase 2 and Phase 3 clinical data are perceived